Ellyris

Ellyris appears to be a small private U.S. biotechnology company organized as Ellyris LLC. Publicly available evidence links the company to early-stage anti-infective research, including scientific work on inhibitors of bacterial hydrogen sulfide biogenesis intended to reduce antibiotic tolerance. The company is referenced in author affiliations and structural biology records rather than through a robust corporate presence, suggesting a very limited operating footprint. No evidence of clinical-stage assets, commercial products, major financing, or an active operating website was found. Based on the available record, Ellyris is best characterized as a likely inactive or dormant preclinical biotech entity associated with translational anti-infective research.